Reader sentiment, not investment advice. One vote per visitor; click again to change it.
CORT last changed hands at $112.45 (down 2.41%). At $12.16B, Corcept Therapeutics is ranked #784 by size among the 800 stocks on BeStock.
The stock's 52-week band runs $28.66 to $126.38, and the latest print sits 11.0% under the top end of it.
The stock changes hands at 249.9 times trailing earnings. The median for its industry group is 33.2.
5 analysts follow the stock and the average call is "buy". The mean target, $141.00, sits 25.4% over where the stock trades.
This summary is put together from the numbers on the page and updates when they do. It describes the data; it is not a forecast or a recommendation.
Composite of 3 factors below, ranked against the 800 U.S. stocks BeStock covers.
Cheaper on P/E than most of BeStock’s coverage scores higher.
Trading closer to its 52-week high than most peers scores higher.
5 analysts, consensus Buy.
How this is scored: each factor above is a 0–100 percentile rank against every other stock BeStock covers (or, for Wall Street, against the five-point Strong Buy–Sell scale). The overall grade is the plain average of whichever factors apply to this stock — no factor is weighted more than another. That average maps to a letter: A ≥ 85, B ≥ 70, C ≥ 50, D ≥ 30, otherwise F. Recomputed from the data on this page as prices and filings update — it describes where a stock ranks today, not a forecast, and not a BeStock recommendation to buy or sell.
CORT is not currently one of the 10 holdings in BeStock Momentum, our rules-based momentum strategy.
Since 2020-07-06, the strategy has returned 1524.8% (321.7% for the equal-weight average of BeStock’s coverage over the same stretch). Holdings can change any trading day, not just on a fixed schedule. Backtested performance, updated weekly — not a guarantee of future results, and not a BeStock recommendation.
What Wall Street analysts and Morningstar's fair-value model expect for the stock
Wall Street’s average 12-month target is $141.00, 25.4% above today’s price, with a consensus rating of Buy.
Figures are Wall Street analyst consensus and Morningstar’s independent fair-value model, sourced as noted above.
Quote as of Oct 1, 2026 12:20 pm ET. Prices can lag the live tape. This is background information, not a recommendation.
Ranks are among the 800 or so U.S.-listed stocks BeStock covers, recalculated whenever prices refresh. A tile is left out when the measure does not apply, such as yield for a stock that pays no dividend.
Set against the peer table: at 249.9x earnings, CORT looks expensive against the market, and trades 654% above the 33.2x median among Biotechnology names. The two comparisons do not always agree.
$112.45 is the latest print for CORT, a move of -2.41% against yesterday's close of $115.23. Today's low and high so far: $111.94 and $115.98.
Equity value comes to $12.16B at the current price. By that measure it is number 784 of the 800 names in our coverage.
Buyers pay 249.9 times the last twelve months of profit (EPS $0.82).
The year's floor is $28.66 and the ceiling $126.38. Shares are 11.0% away from that ceiling.
Our data shows no dividend paid by Corcept Therapeutics over the trailing twelve months.
Of 5 analysts, 80% say buy, 0% hold and 20% sell. Price targets average $141.00, with the most cautious at $50.00 and the most optimistic at $165.00.
BeStock publishes market data and analysis for information only. Nothing here is investment advice or a solicitation to buy or sell any security, and none of it is tailored to your financial situation, goals, or risk tolerance. Quotes may be delayed and figures can contain errors; check primary sources before you trade. How we source and calculate these pages.
No comments yet — be the first to weigh in on CORT.